Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs...
Uloženo v:
| Vydáno v: | Current drug targets Ročník 21; číslo 13; s. 1286 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United Arab Emirates
01.01.2020
|
| Témata: | |
| ISSN: | 1873-5592, 1873-5592 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs on diverse immunostaining platforms. In addition, different scoring systems for PD-L1 immunohistochemistry have been applied in the registration studies regarding single drugs. This review deals with the various issues that are related to the immunohistochemical test for PD-L1. We discuss currently unsolved problems such as the advantages and the flaws of PD-L1 immunohistochemistry; the choice of the best reagents and the best scoring system. Finally, we review the current experiences on the role of immunohistochemistry for PD-L1 in clinical trials with immune checkpoint inhibitors. |
|---|---|
| AbstractList | The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs on diverse immunostaining platforms. In addition, different scoring systems for PD-L1 immunohistochemistry have been applied in the registration studies regarding single drugs. This review deals with the various issues that are related to the immunohistochemical test for PD-L1. We discuss currently unsolved problems such as the advantages and the flaws of PD-L1 immunohistochemistry; the choice of the best reagents and the best scoring system. Finally, we review the current experiences on the role of immunohistochemistry for PD-L1 in clinical trials with immune checkpoint inhibitors.The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs on diverse immunostaining platforms. In addition, different scoring systems for PD-L1 immunohistochemistry have been applied in the registration studies regarding single drugs. This review deals with the various issues that are related to the immunohistochemical test for PD-L1. We discuss currently unsolved problems such as the advantages and the flaws of PD-L1 immunohistochemistry; the choice of the best reagents and the best scoring system. Finally, we review the current experiences on the role of immunohistochemistry for PD-L1 in clinical trials with immune checkpoint inhibitors. The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs on diverse immunostaining platforms. In addition, different scoring systems for PD-L1 immunohistochemistry have been applied in the registration studies regarding single drugs. This review deals with the various issues that are related to the immunohistochemical test for PD-L1. We discuss currently unsolved problems such as the advantages and the flaws of PD-L1 immunohistochemistry; the choice of the best reagents and the best scoring system. Finally, we review the current experiences on the role of immunohistochemistry for PD-L1 in clinical trials with immune checkpoint inhibitors. |
| Author | Giunchi, Francesca Scarpelli, Marina Gevaert, Thomas Fiorentino, Michelangelo |
| Author_xml | – sequence: 1 givenname: Francesca surname: Giunchi fullname: Giunchi, Francesca organization: Department of Pathology S.Orsola-Malpighi Hospital, University of Bologna, Italy – sequence: 2 givenname: Thomas surname: Gevaert fullname: Gevaert, Thomas organization: Department of Development and Regeneration, University of Leuven, Leuven, Belgium – sequence: 3 givenname: Marina surname: Scarpelli fullname: Scarpelli, Marina organization: Department of Pathology University of Ancona, Italy – sequence: 4 givenname: Michelangelo surname: Fiorentino fullname: Fiorentino, Michelangelo organization: Department of Pathology Maggiore Hospital, University of Bologna, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31971109$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtLw0AUhQepaK3-BRl3dRGdO68ky9L6KAQsVDduwszk5gFJpuax6L83YgVX51t8XO45V2TW-hYJuQP2wCGUjyCiWCoGHLTWnE0ggEst-RmZQxSKQKmYz_7xBbkUEIcALJ6Tz_1ghrGnPqe7zhedaRrM6AbNUNKkKkybUaDL3SZI4J7aI902zdj6suoH70pspuyO9MfaO99VbUFXdTHBUDb9NTnPTd3jzSkX5OP56X39GiRvL9v1KgmsAjYEzoksF2hyJyEyWtkwcsxpUILHTsSaWQ4YorEs0xmiYVahc1yhjUwYs5AvyPL37qHzXyP2Qzq95bCuTYt-7FMupORiEuWk3p7U0U4900NXNaY7pn978G96kGKk |
| CitedBy_id | crossref_primary_10_3390_cancers13020292 crossref_primary_10_1016_j_humpath_2024_01_008 crossref_primary_10_1016_j_oraloncology_2022_106086 crossref_primary_10_1016_j_critrevonc_2023_104084 crossref_primary_10_3390_cancers12071800 crossref_primary_10_3389_fonc_2022_779786 crossref_primary_10_3390_jcm13051240 crossref_primary_10_1016_j_ijrobp_2024_07_2316 crossref_primary_10_1007_s10549_024_07487_4 |
| ContentType | Journal Article |
| Copyright | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| Copyright_xml | – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| DBID | NPM 7X8 |
| DOI | 10.2174/1389450121666200123124642 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 1873-5592 |
| ExternalDocumentID | 31971109 |
| Genre | Journal Article |
| GroupedDBID | NPM 7X8 |
| ID | FETCH-LOGICAL-b510t-cc3df3eafc418a65b78c0c615329c3960b21e7eab0d6deea0b5ecc25eb8a79072 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 11 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000581913300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1873-5592 |
| IngestDate | Fri Jul 11 09:09:53 EDT 2025 Thu Jan 02 22:56:27 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Keywords | PD-L1 algorithms immunohistochemistry scoring systems immunotherapy Cancer |
| Language | English |
| License | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b510t-cc3df3eafc418a65b78c0c615329c3960b21e7eab0d6deea0b5ecc25eb8a79072 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 31971109 |
| PQID | 2344230724 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2344230724 pubmed_primary_31971109 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-01-01 |
| PublicationDateYYYYMMDD | 2020-01-01 |
| PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United Arab Emirates |
| PublicationPlace_xml | – name: United Arab Emirates |
| PublicationTitle | Current drug targets |
| PublicationTitleAlternate | Curr Drug Targets |
| PublicationYear | 2020 |
| Score | 2.3275456 |
| SecondaryResourceType | review_article |
| Snippet | The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1286 |
| Title | Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31971109 https://www.proquest.com/docview/2344230724 |
| Volume | 21 |
| WOSCitedRecordID | wos000581913300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1JS8NAFIAHN8SLC251YwQPehiazGSynKRYRaGWggvFS5lMXmpBk2qq4L_3vWmKJ0HwEnLIkGGWN99b5j3GThRYrTKtRAYWUEHRgTC46QTEYD1rtU1cSqHHTtTtxv1-0qsNblUdVjmTiU5QZ6UlG3lTqiCgoGUZnI_fBFWNIu9qXUJjni0qRBla1VHf3X6LIyUQluUyO6ZoZ-TuJrnkAk05zBDZpYMJPNxCKtL-G1y6Q-Zq7b_dW2erNV7y1nQ9bLA5KDbZExHlR8XLnPem4Vj4a94m-OOd0dAUGff5aa8tOv4ZT7_4Dd0ZKV0mYjurB8fpqzvrwvV462WIL5Pn12qLPVxd3l9ci7qmgkhx902EtSrLFZjcBn5sQp1GMc4JUZ9MrEJ1JpU-RGBSLwszAOOlGidZakhjE6EiLbfZQlEWsMt4GuQR8kxoABBivDCxUmUJ6Fz5eex7tsGOZ0M1wK6SI8IUUH5Ug5_BarCd6XgPxtPkGgMUCRFlQd37Q-t9tiJJ_XUWkQO2mOOOhUO2ZD8no-r9yC0GfHZ7t9-9i76j |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Status+of+Programmed+Death+Ligand+1+%28PD-L1%29+by+Immunohistochemistry+and+Scoring+Algorithms&rft.jtitle=Current+drug+targets&rft.au=Giunchi%2C+Francesca&rft.au=Gevaert%2C+Thomas&rft.au=Scarpelli%2C+Marina&rft.au=Fiorentino%2C+Michelangelo&rft.date=2020-01-01&rft.eissn=1873-5592&rft.volume=21&rft.issue=13&rft.spage=1286&rft_id=info:doi/10.2174%2F1389450121666200123124642&rft_id=info%3Apmid%2F31971109&rft_id=info%3Apmid%2F31971109&rft.externalDocID=31971109 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1873-5592&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1873-5592&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1873-5592&client=summon |